Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy

• DOI: 10.1200/jco.2006.24.18_suppl.3535
• Publication Date: 2020-03-09T19:51:54Z
• Authors: M. Sugrue; M. Kozloff; J. Hainsworth; S. Badarinath; A. Cohn; P. Flynn; R. Steis; W. Dong; S. Sarkar; A. Grothey
• Keywords: Perforation

3535 Background: Bevacizumab (BV) prolongs overall survival and progression-free when added to standard chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC). BRiTE is a large, community-based observational registry of pts mCRC receiving BV plus first-line (CT). Incidence rate, temporal pattern, potential risk factors associated gastrointestinal perforation (GIP) were explored. Methods: Baseline patient characteristics (BC), including prospectively identified for GIP, collected at study entry. Safety data every 3 months (mo). Logistic regression models, adjusted unadjusted treatment assignment, used identify BC potentially GIP. Results: 1968 enrolled between Feb 2004 Jun 2005. Median follow-up was 10 mo as Nov 4, GIPs observed 34 (1.7%). For median time first event 2.1 mo; the majority events non-fatal occurred within after starting BV. GI medical history (chronic aspirin or NSAID use, peptic ulcer disease, diverticulosis) similar without GIP earlier later onset (≤ >3 from start BV). Although models did not show any significant BC, rates numerically higher primary tumor intact (2.6%) vs. resected (1.6%). Furthermore, univariate analyses revealed difference (2.3%) (0.8%) (≤3 The had least one following: acute diverticulitis, intra-abdominal abscess, obstruction, site, abdominal carcinomatosis, prior pelvic radiation therapy. Conclusions: Preliminary indicate incidence this that previously reported phase III trials No associations specific BCs an increased identified. Patients more likely incur CT. [Table: see text]